Search results for " 2016"
Article
mAbs to Watch in 2016
And there may be many more of these types of proteins on the horizon—as many as 14 are projected to hit the market in 2016, according to data compiled by EvaluatePharma, in collaboration with BioPharm…
Article
Biopharma in 2016: Higher Quality Drugs, Less Expensive Manufacturing
Despite the advent of regulations and technical capabilities, market leaders at Interphex 2016 expressed their confidence to Process Development Forum that continuous processing, ripe with innovation,…
Article
Framing Biopharma Success in 2016
More than half of the respondents (52%) predicted that their company’s business will improve in 2016; more than one-third (34%) expected no significant change.
Framing the 2016 agenda
Early in…
Article
A Q&A on Bioprocessing Trends and Technologies at INTERPHEX 2016
One sign of progress was the opening of a JHL Biotech flexible manufacturing facility in Wuhan, China on May 10, 2016, for the manufacture of biosimilars and monoclonal antibodies (mAbs). The facility…
Article
Innovative Therapies Require Modern Manufacturing Systems
More biosimilars are poised to come to market in 2016 following FDA approval of the first such therapy in 2015. At the same time, though, the development of such innovative and targeted therapies heig…
Article
Leveraging Computational Models of Glycosylation for Biopharma QA
Close collaboration between academic and industrial groups is vital to ensuring glycosylation models are fit for deployment.
By Ioscani Jiménez del Val
Good Studio/S…
Article
N-Glycan Analysis of Biotherapeutic Proteins
Launch Gly-Q System for Integrated N-Glycan Analysis,” Press Release (Hayward, CA, November 2016).
44. A. Eckhardt, “Rapid and Robust N-Glycan Profiling Workflow for Therapeutic Proteins with …
Article
The Tide Stays High
Nevertheless, fundraising by emerging biopharma companies held its own in 2016. Financing for emerging bio/pharma from venture capital, public equity, and partnering sources was ahead of 2013 levels, …
Article
Managing Biomanufacturing Capacity Expectations
Figure 2: The top 10 factors creating future capacity constraints, as identified by a survey of biomanufacturers in 2016.
Forecasting long-term demand during the transition from clinical to comm…
Article
Vaccine Development Faces Urgency and Challenges
The campaign has helped move more vaccine candidates through clinical testing to market approval, according to an analysis in the February 2016 special issue on vaccines in the journal Health Affairs …